Efficacy and tolerability of manidipine in the treatment of hypertension in patients with non-diabetic chronic kidney disease without glomerular disease. Prospective, randomized, double-blind study of parallel groups in comparison with enalapril

Journal of Nephrology

Volumn 17, Issue 2, 2004, Pages 261-269

  Del Vecchio, Lucia ^a   Pozzi, Marco ^a   Salvetti, Antonio ^b   Maschio, Giuseppe ^c   Fusaroli, Maurizio ^d   Rovati, Carlo ^e   Antonucci, Francesco ^f   Cascone, Carmelo ^g   Scanferla, Flavio ^h   Panichi, Vincenzo ⁱ   Sturani, Alessandra ^d   Locatelli, Francesco ^a  

^a A MANZONI HOSPITAL   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c Maggiore Hospital   (Italy)

^d SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^e SANTA CHIARA HOSPITAL   (Italy)

^f S Maria del Prato Hospital   (Italy)

^g Civil Hospital   (Italy)

^h Nephrology and Dialysis Unit   (Italy)

ⁱ UNIVERSITY OF PISA   (Italy)

Author keywords

Chronic kidney disease; Enalapril; Hypertension; Manidipine; Progression; Proteinuria

Indexed keywords

ANTIHYPERTENSIVE AGENT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CEFOXITIN; CIMETIDINE; CREATININE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; MANIDIPINE; METHYLDOPA; METOPROLOL; PLACEBO; TRIMETHOPRIM;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; HUMAN; KIDNEY DYSFUNCTION; KIDNEY PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PARALLEL DESIGN; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENOVASCULAR HYPERTENSION; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

AGED; ANTIHYPERTENSIVE AGENTS; CHRONIC DISEASE; DIHYDROPYRIDINES; DOUBLE-BLIND METHOD; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; TREATMENT OUTCOME;

EID: 2942654752     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Peterson JC, Sharon A, Burkart JM, Greene T, Hebert LA, Hunsicker LG, for the Modification of Diet in Renal Disease (MDRD) Study Group. Blood pressure control, proteinuria and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-62.
2. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996; 49: 1379-85.
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. For the Collaborative Study Group: The effect of Angiotensin-Converting-Enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
4. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P, and the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group: Effect of the Angiotensin-Converting-Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency. N Engl J Med 1996; 334: 939-45.
5. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-63.
6. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87.
7. Dworkin LD. Impact of calcium entry blockers on glomerular injury in experimental hypertension. Cardiovasc Drug Ther 1990; 4: 1325-30.
8. Sweeney C, Shultz P, Raji L. Interactions of the endothelium and mesangium in glomerular injury. J Am Soc Nephrol 1990; 1 (suppl): S13-20.
9. Rodicio JL. Renal effects of calcium antagonists with special reference to manidipine hydrochloride. Blood Press 1996; 5 (suppl): S10-5.
10. Saruta T, Suzuki H. Efficacy of manidipine in the treatment of hypertension with renal impairment: a multicenter trial. Am Heart J 1993; 125 (2 Pt 2): 630-4.
11. Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, Sanna G, Gaggi R. Long term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42: 452-8.
12. Cinotti GA, Zucchelli PC. Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies. Nephrol Dial Transplant 2001; 16: 961-6.
13. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155: 1073-80.
14. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood pressure lowering agents: a meta analysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963-74.
15. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719-28.
16. Arima S, Ito S, Omata K, Tsunoda K, Yaoite H, Abe K. Diverse effects of calcium antagonists on glomerular hemodynamics. Kidney Int 1996; 49 (suppl 55): S132-4.
17. Saruta T, Kanno Y, Hayashi K, Konishi K. Antihypertensive agents and renal protection: calcium channel blockers. Kidney Int 1996; 49 (suppl 55): S52-6.
18. Locatelli F, Del Vecchio L, D'Amico M, Andrulli S. Is it the agent or the blood pressure level that matters for renal protection in chronic nephropathies? J Am Soc Nephrol 2002; 13 (suppl): S196-201.
19. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group.. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
20. Locatelli F, Del Vecchio L, Andrulli S, Colzani S. Role of combination therapy with ACE inhibitors and calcium channel blockers in renal protection. Kidney Int 2002; 62 (suppl 82): S53-60.